<code id='27DD706EDF'></code><style id='27DD706EDF'></style>
    • <acronym id='27DD706EDF'></acronym>
      <center id='27DD706EDF'><center id='27DD706EDF'><tfoot id='27DD706EDF'></tfoot></center><abbr id='27DD706EDF'><dir id='27DD706EDF'><tfoot id='27DD706EDF'></tfoot><noframes id='27DD706EDF'>

    • <optgroup id='27DD706EDF'><strike id='27DD706EDF'><sup id='27DD706EDF'></sup></strike><code id='27DD706EDF'></code></optgroup>
        1. <b id='27DD706EDF'><label id='27DD706EDF'><select id='27DD706EDF'><dt id='27DD706EDF'><span id='27DD706EDF'></span></dt></select></label></b><u id='27DD706EDF'></u>
          <i id='27DD706EDF'><strike id='27DD706EDF'><tt id='27DD706EDF'><pre id='27DD706EDF'></pre></tt></strike></i>

          Home / fashion / focus

          focus


          focus

          author:explore    Page View:94183
          Alastair Grant/AP

          LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

          The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

          advertisement

          AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In